Zullo Investment Group’s Heron Therapeutics HRTX Stock Holding History

Zullo Investment Group’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-3,450	Closed	-$8.63K	–	393
2022 Q4	$8.63K	Sell	3,450 -3,000	-47%	-$9.66K	0.01%	512
2022 Q3	$27K	Hold	6,450	–	–	0.02%	346
2022 Q2	$18K	Buy	6,450 +150	+2%	+$602	0.01%	413
2022 Q1	$36K	Buy	6,300 +3,000	+91%	+$22K	0.02%	340
2021 Q4	$30K	Buy	+3,300	New	+$33.7K	0.02%	363

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

VCIM

Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Zullo Investment Group's HRTX Position: Q1 2023 in Review

Zullo Investment Group sold out of Heron Therapeutics (HRTX) in Q1 2023, closing a stake of 3,450 shares — an estimated $8.63K sold.

Zullo Investment Group first reported a position in HRTX in Q4 2021 and held it in 5 quarters. The position peaked at $36K in Q1 2022. 162 funds tracked by Wall St. Rank hold HRTX as of Q1 2023.

Zullo Investment Group reported no remaining Heron Therapeutics position as of Q1 2023 after selling out during the quarter.
Zullo Investment Group sold 3,450 Heron Therapeutics shares in Q1 2023, an estimated $8.63K.
Zullo Investment Group first reported a position in Heron Therapeutics in Q4 2021 and held it in 5 quarters.
Zullo Investment Group's Heron Therapeutics position peaked at $36K in Q1 2022.
162 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2023.

Based on Zullo Investment Group's 13F filing for Q1 2023, filed 25 Apr 2023.